Buoninfante, Alessandra http://orcid.org/0000-0001-6416-8492
Andeweg, Arno http://orcid.org/0000-0002-1817-5920
Baker, Alexander T. http://orcid.org/0000-0001-8232-0531
Borad, Mitesh
Crawford, Nigel
Dogné, Jean-Michel
Garcia-Azorin, David http://orcid.org/0000-0002-3132-1064
Greinacher, Andreas
Helfand, Rita http://orcid.org/0000-0001-5734-0258
Hviid, Anders
Kochanek, Stefan
López-Fauqued, Marta http://orcid.org/0000-0002-1337-7267
Nazy, Ishac
Padmanabhan, Anand http://orcid.org/0000-0003-2519-4377
Pavord, Sue http://orcid.org/0000-0002-0840-5614
Prieto-Alhambra, Daniel
Tran, Huyen
Wandel Liminga, Ulla
Cavaleri, Marco
Article History
Received: 10 August 2022
Accepted: 21 October 2022
First Online: 9 November 2022
Competing interests
: M.B. declared a research grant to institution from AstraZeneca for clinical study. A.P. reported pending/issued patents in the area of anti-PF4 antibodies, HIT, VITT and platelet storage (assigned to Mayo Clinic, Retham Technologies, and Versiti Blood Center of Wisconsin), equity ownership in and serving as an officer of Retham Technologies, and member of the advisory board of Veralox Therapeutics. D.P.A. receives funding from the UK National Institute for Health and Care Research (NIHR) in the form of a senior research fellowship and from the Oxford NIHR Biomedical Research Centre. His research group has received funding from the European Medicines Agency and Innovative Medicines Initiative. His research group has received research grant/s from Amgen, Chiesi-Taylor, GSK, Novartis, and UCB Biopharma. His department has also received advisory or consultancy fees from Amgen, Astellas, Astra Zeneca, Johnson and Johnson, and UCB Biopharma; and speaker fees from Amgen and UCB Biopharma. Janssen and Synapse Management Partners have supported training programmes organised by DPA’s department and open for external participants organized by his department outside the submitted work. AG has received funding from the European Medicines Agency and reports consulting fees from: Aspen, Bayer Vital, Chromatec, Instrumentation Laboratory, Macopharma, Sanofi-Aventis, Roche, GTH e.V., Mylan Germany, Takeda Pharma, Falk Foundation e.V., Dilaflor, outside of this work. Also, AG has a patent Screening Methods for transfusion related acute lung injury (TRALI) with royalties paid to EP2321644, 18.05.2011. All the other authors declared no competing interests.